Human major histocompatibility complex class II-restricted T cell responses in transgenic mice.
Open Access
- 1 July 1994
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 180 (1) , 173-181
- https://doi.org/10.1084/jem.180.1.173
Abstract
Transgenic mice expressing human major histocompatibility complex (MHC) class II molecules would provide a valuable model system for studying human immunology. However, attempts to obtain human class II-restricted T cell responses in such transgenic mice have had only limited success, possibly due to an inability of mouse CD4 to interact efficiently with human MHC class II molecules. To circumvent this problem, we constructed recombinant MHC class II genes in which the peptide-binding domain was derived from human DR sequences whereas the CD4-binding domain was derived from mouse I-E sequences. Purified chimeric human/mouse MHC class II molecules were capable of specifically binding DR-restricted peptides. Human B cell transformants that expressed these chimeric MHC class II molecules could present peptide antigens to human T cell clones. Expression of these chimeric class II molecules in transgenic mice led to the intrathymic deletion of T cells expressing superantigen-reactive V beta gene segments, indicating that the chimeric class II molecules could influence the selection of the mouse T cell repertoire. These transgenic mice were fully capable of mounting human DR-restricted immune responses after challenge with peptide or whole protein antigens. Thus, the chimeric class II molecules can serve as functional antigen presentation molecules in vivo. In addition, transgenic mice expressing chimeric class II molecules could be used to generate antigen-specific mouse T cell hybridomas that were capable of interacting with human antigen-presenting cells.Keywords
This publication has 30 references indexed in Scilit:
- Species-specific binding of CD4 to the beta 2 domain of major histocompatibility complex class II molecules.The Journal of Experimental Medicine, 1992
- Identification of a CD4 binding site on the β2 domain of HLA-DR moleculesNature, 1992
- Capacity of unprimed CD4+ and CD8+ T cells expressing V beta 11 receptors to respond to I-E alloantigens in vivo.The Journal of Experimental Medicine, 1989
- The MHC-Binding and gp120-Binding Functions of CD4 Are SeparableScience, 1989
- Transgenic HLA-DRα faithfully reconstitutes IE-controlled immune functions and induces cross-tolerance to Eα in Eα0 mutant miceCell, 1989
- The MHC molecule I-E is necessary but not sufficient for the clonal deletion of V beta 11-bearing T cells.The Journal of Experimental Medicine, 1989
- A diabetes-susceptible HLA haplotype is best defined by a combination of HLA-DR and -DQ alleles.Journal of Clinical Investigation, 1989
- The Epstein‐Barr Virus Glycoprotein gp110, a Molecular Link between HLA DR4, HLA DR1, and Rheumatoid ArthritisScandinavian Journal of Immunology, 1988
- Molecular mimicry and autoimmune diseaseCell, 1987
- Dw subtypes of DR4 in rheumatoid arthritis: Evidence for a preferential association with Dw4Human Immunology, 1986